Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,043,600 | $1,049,300 | $1,117,500 | $1,773,600 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Cost of Goods Sold | $668,200 | $689,300 | $644,500 | $980,400 |
| Gross Profit | $375,400 | $360,000 | $473,000 | $793,200 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| R&D Expenses | $70,700 | $111,400 | $188,300 | $235,200 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $298,700 | $356,700 | $339,500 | $348,700 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $114,700 | $618,300 | $115,200 | -$132,100 |
| Operating Expenses | $484,100 | $1,086,400 | $643,000 | $451,800 |
| Operating Income | -$108,700 | -$726,400 | -$170,000 | $341,400 |
| % Margin | -10.4% | -69.2% | -15.2% | 19.2% |
| Other Income/Exp. Net | -$34,200 | -$4,800 | -$49,000 | -$38,200 |
| Pre-Tax Income | -$142,900 | -$731,200 | -$219,000 | $303,200 |
| Tax Expense | $47,700 | $29,300 | -$7,400 | $83,700 |
| Net Income | -$190,600 | -$760,500 | -$211,600 | $219,500 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS | -3.6 | -14.85 | -4.47 | 4.1 |
| % Growth | 75.8% | -232.2% | -209% | – |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| Weighted Avg Shares Out | 53,000 | 51,200 | 50,100 | 53,500 |
| Weighted Avg Shares Out Dil | 53,000 | 51,200 | 50,100 | 54,100 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $71,000 | $87,900 | $37,300 | $34,500 |
| Depreciation & Amortization | $105,600 | $121,100 | $125,000 | $118,200 |
| EBITDA | $53,400 | -$47,000 | $15,700 | $504,200 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |